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Abstract
Background: Major depressive disorder (MDD) has been associated with adverse medical consequences, including
cardiovascular disease and osteoporosis. Patients with MDD may be classified as having melancholic, atypical, or
undifferentiated features. The goal of the present study was to assess whether these clinical subtypes of depression have
different endocrine and metabolic features and consequently, varying medical outcomes.
Methods: Premenopausal women, ages 21 to 45 years, with MDD (N=89) and healthy controls (N=44) were recruited for a
prospective study of bone turnover. Women with MDD were classified as having melancholic (N=51), atypical (N=16), or
undifferentiated (N=22) features. Outcome measures included: metabolic parameters, body composition, bone mineral
density (BMD), and 24 hourly sampling of plasma adrenocorticotropin (ACTH), cortisol, and leptin.
Results: Compared with control subjects, women with undifferentiated and atypical features of MDD exhibited greater BMI,
waist/hip ratio, and whole body and abdominal fat mass. Women with undifferentiated MDD characteristics also had higher
lipid and fasting glucose levels in addition to a greater prevalence of low BMD at the femoral neck compared to controls.
Elevated ACTH levels were demonstrated in women with atypical features of depression, whereas higher mean 24-hour
leptin levels were observed in the melancholic subgroup.
Conclusions: Pre-menopausal women with various features of MDD exhibit metabolic, endocrine, and BMD features that
may be associated with different health consequences.
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Introduction
Major Depressive Disorder (MDD) is a common condition with
a lifetime prevalence of 20.8% [1]. According to the Diagnostic
and Statistical Manual of Mental Disorders, (DSM-IV), an episode
of MDD can be classified clinically as depression with melancholic
features and depression with atypical features. Melancholic
depression is characterized by anhedonia, lack of reactivity to
pleasurable stimuli and three or more of the following: loss of
appetite or weight, insomnia, psychomotor retardation or
agitation, sense of guilt, early awakening, depression that is worse
in the morning, and a distinct quality of depressed mood. In
contrast, atypical depression is defined by mood reactivity (mood
brightens in response to positive events), appetite and weight
increase, hypersomnia, leaden paralysis, and pathological sensi-
tivity to perceived interpersonal rejection resulting in social or
occupational impairment. To further define phenotypes of
depressive episodes, distinctive features of clinical subtypes have
been studied, including behavioral manifestations, response to
antidepressants, regional differences in cerebral blood flow,
perceptual asymmetries, electroencephalographic sleep recordings,
and endocrine dysregulations [2–8]. More recently, cognitive
impairment has been reported in subjects with melancholic
depression [9]. MDD is characterized by a high level of clinical
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entity has been criticized [11]. The classification of episodes into
clinical subtypes has been developed in an attempt to limit the
clinical heterogeneity of MDD and is currently being re-evaluated
in preparation of the DSM-V.
The epidemiology of clinical subtypes of depression has been
characterized in the National Comorbidity Survey: 36% of
individuals with MDD had atypical features of hypersomnia and
hyperphagia, and 34% had melancholic features [12]. Atypical
depression is more common in women [13], is associated with an
earlier age of onset [2,14], frequently includes comorbid anxiety
[12,14], or avoidant personality disorder [15,16], and is associated
with drug dependence, suicidal thoughts and attempts, utilization
of health services, physical and sexual abuse or neglect, and
functional disability [12]. In drug trials, the prevalence of atypical
depression ranged from 16% to 42% [16]. Further, patients with
atypical features respond better to monoamine oxidase inhibitors
than to tricyclic antidepressants [4] and may have a smaller
noradrenergic activation than patients with melancholic features
[17].
It is becoming increasingly clear that MDD has a substantial
impact on physical health [18]. In addition to osteoporosis [19,20],
cardiovascular disease [18], and immune alterations [21], MDD
often co-exists with insulin resistance [18], diabetes [22] and
obesity [23]. We conducted the POWER (Premenopausal,
Osteoporosis, Women, Alendronate, Depression) Study, a longi-
tudinal study of bone turnover in women with MDD, to determine
whether major depression was associated with low bone mineral
density. We have recently summarized the most important
findings of this study [24]: MDD was associated with osteopenia,
an increased risk for insulin resistance and cardiovascular disease,
a chronic state of subclinical inflammation, increased diathesis to
coagulopathy states, major endocrine, immune and neuropeptide
alterations, and increased propensity to chronic pain.
The goal of this ancillary study was to determine whether
different clinical subtypes of depression were associated with
specific clinical or laboratory abnormalities. Thus, we character-
ized metabolic features, bone mineral density, and endocrine
circadian profiles in the clinical subtypes of MDD using validated
clinical markers. Our exploratory hypothesis was that individual
clinical subtypes would be associated with different endocrine and
metabolic features.
Methods
Participants
Study participants were premenopausal women, ages 21 to 45
years who enrolled in the POWER (Premenopausal, Osteoporo-
sis, Women, Alendronate, Depression) Study, a longitudinal study
of bone turnover in women with MDD [20]. Recruitment was
conducted from July 2001 to February 2003 in the Washington,
DC metropolitan area by advertising in newspapers, radio,
Internet, and flyers. Written informed consent was obtained from
all study participants. This study was approved by the
Institutional Review Board of the National Institute of Mental
Health.
Psychiatric assessment
Participants were evaluated by clinicians trained in the use of
the Structured Clinical Interview for DSM-IV for Axis I disorders,
Patient Edition (SCID-IV I/P), version 2.0 [25], to diagnose
unipolar MDD, according to criteria from the DSM-IV (American
Psychiatric Association 1994) or to rule out any DSM-IV Axis I
diagnosis (healthy controls). To minimize recall bias, an additional
inclusion criterion for women with depression was having had an
episode of MDD within the past three years. Melancholic and
atypical subtypes were classified according to the most recent
depressive episode. Patients that did not meet criteria for
melancholic or atypical depression were classified as unspecified.
Lifetime history of depression was estimated, including the
number of depressive episodes and their length. Symptoms of
depression and anxiety over the past week were assessed with the
Hamilton Scale for Depression (HAM-D, 24 items) and the
Hamilton Scale for Anxiety (HAM-A, 14 items).
Patients with bipolar disorder, current alcohol abuse or
dependence, recent drug abuse or dependence, history of
psychosis, anorexia or bulimia, or those at suicidal risk were
excluded. Past or current comorbid anxiety and past binge eating
disorder were not exclusionary criteria. As previously reported,
120 women with self-reported depression were screened, of whom
89 entered the study [20]. Women with MDD were classified
according to the DSM-IV criteria as melancholic (n=51) or
atypical (n=16). Depressed women whose last MDD episode had
features of both melancholic and atypical depression, but did not
meet criteria for either subgroup and those who met criteria for
neither subgroup, were classified as having undifferentiated
depression (n=22). None of the patients with MDD had
symptoms of psychosis, catatonia, or postpartum depressive
features. Most patients were taking selective serotonin reuptake
inhibitors (SSRIs), and no patient was taking tricyclic or
monoamine oxidase inhibitors (MAOI). Sixty-three healthy
controls were screened and of those, 44 women with no DSM-
IV diagnoses other than past (not within the past five years) alcohol
abuse were admitted into the study. Control subjects were
excluded if they had any DSM-IV axis I diagnosis. Controls were
matched to subjects with MDD based on age (63 years) and BMI
(62 units), and blinded to the clinical subtype of subjects with
depression. Except for two pairs, participants were matched by
race as well.
Medical assessment
All participants were in good physical health, as assessed by
history and medical examination at screening. Menopause,
defined as the absence of spontaneous menses during the
preceding 6 months, was an exclusion criterion. Estrogen/
progestin contraception was allowed, if unmodified for at least 6
months prior to enrollment.
Anthropometric measurements
Body weight was measured to the nearest 0.1 kg using a
platform digital scale; height was measured to the nearest 0.1 cm
using a stadiometer. BMI was calculated as weight in kilograms
divided by the square of height in meters (kg/m
2) [26]. Waist
circumference (WC) was measured with a non-stretch tape to the
nearest 0.1 cm at the level of the uppermost lateral border of the
right iliac crest. The mean of three measurements was used for
analysis.
Frequent blood sampling
Hourly blood collections were performed during a 24-hour
period on 87 women who were available to complete an inpatient
hospital stay: 32 with melancholic, 15 with undifferentiated, and
10 with atypical MDD features; and 30 healthy controls. Women
were admitted to the inpatient unit the day before blood sampling
began. Participants were placed on an ad libitum diet. Lights went
off at 11 PM. Fasting blood was collected at 8 AM and then
samples were taken at 1-hour intervals until 8 AM the next day for
a total of 25 samples. Approximately one hour prior to sample
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the IV line was connected to the Venous/Arterial Blood
Management Protection System (VAMPH, Edwards Lifescience
Irvine, CA), a device that permits undiluted blood samples to be
obtained from an in-line sampling site. The arm with the sampling
catheter was maintained in a heating blanket to ensure
arterialization of the venous sample. Blood samples were then
placed in pre-chilled tubes using ethylenediaminetetraacetic acid
as an anticoagulant. Approximately 0.3 liters of blood were drawn
in total.
Bone mineral density and body composition
Bone mineral density (BMD) and whole body composition were
assessed by dual energy X-ray absorptiometry (DXA) scan, using
the Hologic DXA QDR 4500 (Bedford, MA). The coefficient of
variation for BMD was ,0.4%. A radiologist (JCR) reviewed the
DXA films and reported the percentage of fat for the whole body
and the abdominal area extending from the T12/L1 interface to
the L4/L5 interface, which includes both visceral and subcutane-
ous fat.
Cooper test (12-minute walk/run test)
The Cooper test, which measures the distance covered during
12-minutes by running or walking as fast as possible, was used as
an indirect index of physical fitness [26].
Blood tests
Plasma ACTH and serum cortisol concentrations were
measured using competitive chemiluminescent immunoassays
(Nichols Advantage analyzer, San Juan Capistrano, CA, for
ACTH; DPC Immulite-2000 analyzer, Los Angeles, CA, for
cortisol) at the NIH Clinical Center Department of Laboratory
Medicine. Inter-/intra-assay coefficients of variation (CV’s) were
all ,10%. Plasma leptin was measured by ELISA (Linco Research
Inc., St. Charles, MI) at Covance Laboratories (Vienna, VA), with
inter-/intra-assay CV,10%. Fasting glucose and insulin levels
were determined from the 8 AM sample, and insulin resistance
was calculated using the homeostasis model for insulin resistance
(HOMA-IR), a useful indicator of insulin resistance in patients
with diabetes mellitus type 2 and an independent predictor of
cardiovascular disease [27].
Statistical analyses
Differences of means among groups were compared by analysis
of variance (ANOVA), with pre-planned comparisons of each of
the three MDD clinical subtypes with controls, using SAS PROC
GLM (SAS Institute, Cary, NC). In case of a significant main
group effect (control and the three MDD subtypes), post hoc
comparisons between MDD subtypes were conducted using
Tukey’s least significant difference method. Categorical outcome
measures were compared by Fisher’s exact test.
The proportion of women with low BMD (t-score,21.0) at the
AP spine, femoral neck, or total femur was compared using logistic
regression. To test for differences in the proportion of low BMD at
any one or more of the three skeletal sites between women in each
subtype and controls, a generalized estimating equation (GEE)
model, in which the three bone sites are treated as repeated
measures within each subject, was applied [28]. Analyses of BMD
measures were adjusted for BMI.
Leptin and ACTH values were log transformed because of
positive skewedness and were normalized, as verified by the
Shapiro-Wilkes test. ACTH, cortisol, and leptin were each
compared in repeated measures with mixed model analyses, using
SAS PROC MIXED, where adjacent time-points were averaged
for each subject, for a total of 12 values. In these analyses, the
main effect of clinical subtype and its interaction with time of day
were tested. Each depressive subtype was compared with controls
in pre-planned contrasts. In case of a significant interaction,
individual time points were compared and reported as significantly
different if p,0.01. All data was reported as mean 6 standard
deviation (SD). Two-sided level of significance was set at a nominal
0.05 value, unless otherwise specified.
Results
Demographic characteristics and clinical features of
depression
Table 1 reports the demographic and psychosocial character-
istics. Women with undifferentiated MDD were slightly older and
had greater BMI than controls. Women with atypical features
were heavier, had an earlier age of menarche, were less often
married, and less conditioned than controls. Women with
melancholic features had demographic features similar to controls.
Use of oral contraceptives, history of smoking, and alcohol use did
not differ amongst the groups.
The clinical characteristics are described in Table 2. Patients
were, on average, mildly depressed or in clinical remission, as
indicated by Hamilton depression and anxiety scores. However,
about 17% of depressed women had experienced an episode of
major depression within the past month (data not shown), and
most had an average of four episodes and five years of cumulative
time in depression. Age of onset of depression for the three
subgroups was in the late teens. The most common comorbid Axis
I diagnoses were anxiety disorders, present in 44% of depressed
women and in similar proportions among the depressive subtypes.
More than 80% of depressed patients were taking antidepressants,
and approximately 15% used anxiolytics. Specifically, women with
undifferentiated features had spent longer time in depressive
episodes than women with atypical features.
Metabolic, body composition, and bone mineral density
measures
Women with undifferentiated features had more total fat,
abdominal fat, and greater waist to hip ratio than controls
(Table 3). Consistently, this group had a higher LDL, log
triglycerides, and total cholesterol levels, as well as higher fasting
glucose, insulin levels, and HOMA-IR compared to controls. After
adjusting for whole body percent fat mass, the following remained
significant: least squares adjusted means 6 SD for undifferentiated
vs. control, LDL, 123.6627.0 vs. 108.0627.1, p,0.05; log
triglycerides, 4.760.50 vs. 4.360.51, p,0 .002; total cholesterol,
196.4631.0 vs. 174.8631.1, p,0.02; and fasting glucose,
93.569.5 vs. 88.169.5, p,0.05. Women with atypical features
had more total body and abdominal fat, as well as greater waist/
hip ratio than controls. Women with melancholic features did not
differ from controls in their metabolic profiles.
Women with undifferentiated depression had a significantly
higher prevalence of low BMD at the femoral neck than controls.
Furthermore, GEE analysis indicated that low BMD at any of the
three sites was more common in each subtype of depression than
in controls. Odds ratios for low BMD were as follows:
undifferentiated group: 6.81 (95% CI: 1.93–24.77, p,0.004);
atypical group 5.83 (95% CI: 1.63–20.92, p,0.007); melancholic
group: 4.22 (95% CI: 1.44–12.39, p,0.009). Higher mean 8 AM
cortisol levels for all women were associated with low BMD
(p,0.0001).
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Clinical Characteristic Undifferentiated (n=22) Atypical (n=16) Melancholic (n=51)
Age of Onset 17.568.6 (n=17) 21.669.6 (n=14) 18.969.2 (n=34)
Number of Depressive Episodes 4.562.3 (n=17) 4.162.5 (n=14) 4.462.8 (n=34)
Months with Symptoms of Depression
(Lifetime)
113.06121.4 (n=17) 35.7633.8
b (n=14) 59.8654.4 (n=34)
Global Assessment of Function (GAF) 6569.1 6168.2 62610.0 (n=49)
Hamilton Scale for Depression 9.768.0 (n=19) 11.668.1 8.165.3 (n=46)
Hamilton Scale for Anxiety 7.866.2 (n=19) 7.764.8 6.564.2 (n=46)
Other Axis I Diagnoses
Post-Traumatic Stress Disorders 22.7% 12.5% 8.2% (n=49)
Obsessive compulsive disorders 9.1% 6.3% 2.0% (n=49)
Any anxiety disorder 50.0% 56.3% 36.7% (n=49)
History of binge eating 4.6% 0% 2.0%
History of drug abuse 4.6% 37.5% 10.2% (n=49)
History of alcohol abuse 31.3% 37.5% 16.3%
Medications
Antidepressants 90.9% 81.3% 84.3%
Anxiolytic 13.6% 19.8% 11.8%
Values are reported as mean 6 SD or percent.
Sample size in parenthesis, unless otherwise indicated.
Significant comparisons, assessed as p#.05 nominal value.
bAtypical differed from undifferentiated.
doi:10.1371/journal.pone.0028912.t002
Table 1. Demographic characteristics of depressive subtypes of women with unipolar MDD.
Depressive Subtype
Characteristics Healthy Controls (n=44) Undifferentiated (n=22) Atypical (n=16) Melancholic (n=51)
Age (yrs) 34.766.8 38.265.4
b 34.367.8 34.367.0
Body mass index (kg/cm
2) 24.263.7 27.266.2
b 28.967.1
a 25.866.0
Weight (kg) 68.0610.6 74.2618.8 80.5621.2
a 70.4617.3
White race 86.4% 90.9% 75.0% 90.2%
Years of education 16.362.1 16.962.0 15.161.9
a 16.761.9
Married (%) 50.0% 54.6% 18.8%
a 31.4%
Ever Smoked 31.8% 27.3% 50.0% 28.1% (9/32)
Age at Menarche 13.061.6 (n=43) 12.761.6(n=20) 11.961.6
a(n=15) 12.561.6 (n=47)
Previous pregnancies 1.2361.36 1.7361.70 1.5662.13 0.8861.31
Contraceptive Pill Users 36.4% 18.2% 31.3% 35.3%
Estimated Total Calcium
Intake (mg/day)
14086755(n=41) 14316844(n=19) 15716699(n=14) 13156561(n=45)
Alcohol Consumption
(g/week)
6.9611.6(n=41) 5.064.8 3.966.1 4.366.2
Distance covered in the
Cooper test (m)
14386280(n=23) 12526253(n=11) 11296192
a(n=7) 14096370(n=20)
Values are reported as mean 6 SD or percent.
Sample size in parenthesis, unless otherwise indicated.
Significant comparisons, assessed as p#.05 nominal value.
Overall: overall test.
aAtypical differs from control.
bUndifferentiated differs from control.
doi:10.1371/journal.pone.0028912.t001
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Twenty-four hour plasma ACTH, cortisol, and leptin secretion
are depicted in Figure 1. Mean 24-hour plasma ACTH
concentrations were higher in the atypical subtype vs. the control
group (F (1, 83)=4.01, p,0.05), as well as in the melancholic vs.
control group (F (1, 83)=6.89, p=0.01). In addition, a significant
group by time interaction (F (33, 909)=2.38, p,0.0001) revealed
that ACTH was elevated in the atypical group only in the daytime
(Figure 1), with the greatest differences between atypical and
controls from 10 AM to 5 PM (all p,0.01). These differences
remained significant after adjustment for BMI.
No differences in mean 24-hour plasma cortisol values were
observed. After adjustment for total body fat, the mean 24-hour
adjusted log leptin value was elevated in the melancholic
subgroup, as compared with controls (adjusted means=2.84
melancholic vs. 2.63 control; F (1, 66)=5.17, p,0.03).
Discussion
The three different phenotypes of depression exhibited distinct
features compared to control subjects; women with atypical or
undifferentiated MDD exhibited greater BMI, waist/hip ratio,
whole body and abdominal fat mass, and higher mean 24-hour
ACTH levels. (Table 4). Women with melancholic features had
higher mean 24-hour leptin levels than controls. Finally, women
with undifferentiated depression exhibited higher fasting lipids,
glucose, and insulin levels; and had a greater prevalence of low
BMD at the femoral neck than controls.
Metabolic features
B o t hw o m e nw i t ha t y p i c a lo ru n d i f f e r e n t i a t e dd e p r e s s i o n
were heavier than controls. The greater BMI, waist circumfer-
ence, and fat mass are consistent with the hyperphagia that
distinguishes atypical depression. The NESDA Study, a large
cohort study conducted in the Netherlands reported also higher
body weight, a greater prevalence of metabolic syndrome, and
more somatic symptoms in subjects with atypical depression
[29]. Women with undifferentiated depression had significantly
higher fasting glucose and insulin and HOMA index [30].
Specifically, the average HOMA index in this subgroup, 2.4,
approached the accepted cut-off for insulin resistance, 2.6. In
keeping with our findings, a recent meta-analysis reported a
strong association between depression and type 2 diabetes, with
a 60% increased risk in depressed subjects of developing
diabetes over time [31]. We also examined lipid parameters:
subjects with undifferentiated depression had higher LDL,
tryglicerides and total cholesterol than controls. Some of the
altered measures are part of the definition of metabolic
syndrome;. MDD and metabolic syndrome co-occur, and may
be related to each other in a bi-directional way, as they share
common pathogenetic mechanisms, including elevated proin-
flammatory cytokines and glucocorticoids [32]. Whether women
with undifferentiated depression have a greater risk for diabetes
and cardiovascular disease than other clinical subtypes of
depression, particularly after menopause when losing the
protective effects of estrogens, remains to be determined in
prospective studies.
Table 3. Metabolic, body composition, and bone mineral density measures.
Depressive Subtype
Characteristic Healthy Controls (n=44) Undifferentiated (n=22) Atypical (n=16) Melancholic (n=51)
Body Composition
Whole Body Fat Mass (gm) 2188766574 28155611896
c 30586615164
a 24716610996
Whole Body Lean Mass (gm) 4722866271 4740968476 5071268122 4630367575
Whole Body % Fat 31.2%65.5 36.166.5
c 35.5%69.3
a 33.4%67.7
Abdominal % Fat 22.7%67.5(n=30) 29.2%69.6
c(n=15) 29.6%612.5
a(n=11) 26.1%610.1(n=34)
Waist/Hip Ratio 0.7560.05(n=41) 0.8160.05
c(n=19) 0.7960.07
a(n=13) 0.7760.05(n=43)
Lipids (n=41) (n=19) (n=15) (n=46)
HDL (mg/dL) 58.8611.5 55.9615.5 55.9614.7 57.3612.8
LDL (mg/dL) 106.0622.6 126.1633.0
c 118.8631.9 116.2628.4
Log Triglycerides (mg/dL) 4.2560.40 4.7660.69
c 4.4460.61 4.5660.78
b
Total Cholesterol (mg/dL) 173.4625.7 198.1635.8
c 186.9632.7 181.8632.8
Glucose metabolism (n=41) (n=19) (n=15) (n=46)
Fasting Glucose (mg/dL) 87.669.5 94.1611.8
c 85.965.4 88.269.6
Insulin (mcU/mL) 6.0664.28 9.7268.16
c 9.6465.63 7.7065.12
HOMA-IR 1.4661.13 2.3762.16
c 2.0361.11 1.7261.29
Percent prevalence of low BMD (T score,21)
AP Spine 9.1 18.2 18.8 21.6
Femoral Neck 2.3 27.3
c 18.8 11.8
Total Femur 2.3 18.2 12.5 13.7
Values are reported as mean 6 SD or percent.
Sample size in parenthesis, unless otherwise indicated.
Significant comparisons, assessed as p#.05 nominal value.
aAtypical differs from control.
bMelancholic differs from control.
cUndifferentiated differs from control.
doi:10.1371/journal.pone.0028912.t003
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HPA Axis. We measured hourly plasma levels of ACTH and
cortisol for 24 hours in different subtypes of depression.
Alterations of the HPA axis in depression are a reliable finding
in biological psychiatry. These abnormalities are however mostly
observed during the depressive episodes and relate to clinical
severity. The typical circadian profile of ACTH and cortisol, two
pulsatile hormones, was preserved in the three clinical subtypes.
This is consistent with the fact that most of these women were not
depressed at the time of sampling and in clinical remission. We
nevertheless observed some subtle differences compared to
controls. Women with melancholic and atypical features of
depression had higher plasma ACTH levels compared with
controls. Higher plasma ACTH may be secondary to a
dysregulation of the CRH hypothalamic neuron [33], reduced
negative feedback of the pituitary corticotroph by cortisol,
impaired response of the adrenals to ACTH, as well as a
combination of all these factors. Although the majority of these
patients were taking antidepressants, it is unlikely that higher
plasma ACTH levels were due to pharmacological treatment as
higher plasma ACTH has been reported in a cohort of women
with untreated atypical features of depression [34]. A recent meta-
analysis found no differences in ACTH levels in clinical subtypes
[35]; however repeated sampling over 24 hours may unravel
abnormalities not evident with single plasma sampling. Alterations
in ACTH secretion have been reported in depression; with 10 min
sampling over 24 hours Young et al. [36] demonstrated less
‘‘orderly’’ ACTH secretion, as indicated by increased entropy in
non-medicated premenopausal women with depression.
Plasma leptin. Women with melancholic depression had
higher leptin levels compared to controls. In a related study, we
reported that 24-hour plasma leptin levels were about 30% higher
in a subset of 23 women with depression compared to 23 BMI -
matched controls [37]. Because leptin provides satiety cues to the
brain [38], it may explain the lack of appetite in melancholic
depression. Higher levels of plasma leptin in patients with
melancholic depression may have been caused by increased
sympathetic tone. Catecholamines stimulate leptin secretion [39]
and CSF and plasma norepinephrine and epinephrine are
increased in patients with melancholic depression [40]. A leptin
hypothesis linking mood disorder and obesity, two largely
overlapping conditions at the population level, has been
formulated [41]. Extra-hypothalamic actions of leptin are
beginning to emerge; these include antidepressant and
mnemonic effects [42]. Inappropriately higher leptin levels for
body weight in depressed subjects are reminiscent of
inappropriately elevated leptin levels in obese subjects. Future
studies should determine if subjects with depression develop a
resistance to the antidepressant effects of leptin when gaining
weight.
Reproductive history. Women with atypical depression had
menarche approximately one year earlier (12 vs. 13) than control
subjects. This age was, however, well within normative age, which
is 12.5 in the US, based on the NHANES data [43]. In addition,
given the study design, sampling bias may have contributed to the
difference in age at menarche. Nevertheless, it should be noted
that the risk of depression increases with decreasing age at
menarche, as data from the Harvard Study of moods and cycle, a
large population-based study, suggested using a nested case-
control approach [44].
BMD features
The existence of an association between major depression and
osteoporosis has been well documented [19,45], and the endocrine
and immune mechanisms at play have been summarized in recent
reviews [24,46]. In this study we analyzed the relationship between
major depression and osteoporosis based on clinical subtypes. We
found that osteopenia at the femoral neck was more prevalent in
Table 4. Synopsis of significant findings in the three subtypes of depression vs. healthy controls.
Undifferentiated Atypical Melancholic
BMI X
Weight X
Percent married Y
Age at menarche Y
Physical conditioning (Cooper Test) Y
Months of symptoms of depression (Lifetime
depression)
Y
Waist circumference X
Fat mass XX
Abdominal fat mass X
Fasting glucose X
Fasting insulin X
HOMA X
LDL X
Triglycerides X X
Total cholesterol X
Prevalence of low BMD X (femoral neck)
ACTH (After adjustment for BMI) XX
Leptin (after adjustment for body fat) X
doi:10.1371/journal.pone.0028912.t004
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morning cortisol levels were associated with low bone mass, but
did not discriminate between the subtypes.
Study limitations and strengths
The following study limitations should be noted. Most women
were on antidepressants, anxiolytics, and/or oral contraceptives;
these medications may have affected some of the outcome
measures. In addition, the frequency of blood sampling did not
allow for hormone pulsatility analyses, and no dynamic endocrine
testing was performed. Since the study was not specifically
designed to assess phenotypic differences in clinical subtypes, the
sample size was uneven among groups. The current analysis of
phenotypic differences among clinical subtypes was of exploratory
nature and the current findings should be regarded as hypothesis
generating. On the other hand, this sample was prospectively
assembled; homogeneous; carefully characterized in terms of
clinical, endocrine, metabolic, and bone mass parameters; and a
relatively large number of subjects underwent frequent sampling.
Overall clinical and pathophysiological relevance
The current findings suggest that among the three clinical
subtypes, undifferentiated depression may carry the greatest
cardiovascular morbidity and increased risk of diabetes and hip
fractures. Historically, the construct of depressive subtypes was
developed based on clinical symptoms and response to antide-
pressants. This study suggests that these subtypes may indeed be
biologically rooted and have distinct medical consequences.
In summary, we found that different clinical subtypes of
depression were associated with specific bone, metabolic, and
endocrine features. Our findings lend support to the idea that
depressive subtypes are not mere clinical entities but are rather
distinct nosological entities, possibly underlying a differential
dysregulation of the CRH hypothalamic neuron in depressive
subtypes. Future studies should determine the extent to which
these distinct features translate into differential medical morbidity,
the genetic predisposition to different clinical phenotypes, and the
stability of these traits over the lifetime.
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